| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intestinal Mucosa | 84 | 2022 | 157 | 12.740 |
Why?
|
| Gastrointestinal Microbiome | 49 | 2023 | 124 | 11.810 |
Why?
|
| Ethanol | 54 | 2022 | 82 | 11.600 |
Why?
|
| Circadian Rhythm | 31 | 2022 | 213 | 8.350 |
Why?
|
| Inflammatory Bowel Diseases | 37 | 2023 | 80 | 7.800 |
Why?
|
| Colon | 52 | 2023 | 112 | 6.980 |
Why?
|
| Intestines | 39 | 2022 | 77 | 6.180 |
Why?
|
| Parkinson Disease | 22 | 2023 | 591 | 5.160 |
Why?
|
| Colitis, Ulcerative | 35 | 2022 | 57 | 4.920 |
Why?
|
| Alcoholism | 24 | 2022 | 64 | 4.680 |
Why?
|
| Liver Diseases, Alcoholic | 17 | 2020 | 31 | 4.160 |
Why?
|
| Microbiota | 21 | 2023 | 65 | 4.040 |
Why?
|
| Humans | 293 | 2023 | 22947 | 4.000 |
Why?
|
| Animals | 116 | 2023 | 3295 | 3.940 |
Why?
|
| Dysbiosis | 16 | 2023 | 36 | 3.700 |
Why?
|
| Inflammation | 23 | 2023 | 231 | 3.530 |
Why?
|
| Alcohol Drinking | 16 | 2020 | 65 | 3.530 |
Why?
|
| Feces | 32 | 2023 | 80 | 3.350 |
Why?
|
| Permeability | 43 | 2022 | 94 | 3.070 |
Why?
|
| Male | 188 | 2022 | 12458 | 3.050 |
Why?
|
| Intestinal Absorption | 19 | 2017 | 30 | 2.840 |
Why?
|
| Gastrointestinal Tract | 14 | 2019 | 41 | 2.830 |
Why?
|
| Oxidants | 20 | 2011 | 27 | 2.770 |
Why?
|
| Oxidative Stress | 27 | 2017 | 81 | 2.670 |
Why?
|
| Epithelial Cells | 14 | 2022 | 70 | 2.460 |
Why?
|
| Epidermal Growth Factor | 14 | 2007 | 26 | 2.420 |
Why?
|
| Cytoskeleton | 19 | 2009 | 33 | 2.400 |
Why?
|
| Protein Kinase C | 13 | 2005 | 47 | 2.390 |
Why?
|
| Endotoxemia | 11 | 2018 | 19 | 2.360 |
Why?
|
| Mice | 46 | 2023 | 1250 | 2.210 |
Why?
|
| Gastrointestinal Diseases | 8 | 2019 | 26 | 2.170 |
Why?
|
| Female | 133 | 2022 | 12954 | 2.080 |
Why?
|
| Quality of Life | 9 | 2022 | 559 | 2.040 |
Why?
|
| Microtubules | 13 | 2004 | 26 | 2.020 |
Why?
|
| Mice, Inbred C57BL | 32 | 2023 | 370 | 2.020 |
Why?
|
| Adult | 98 | 2022 | 6923 | 2.000 |
Why?
|
| Liver | 13 | 2020 | 137 | 2.000 |
Why?
|
| Bacteria | 17 | 2022 | 61 | 1.970 |
Why?
|
| Caco-2 Cells | 34 | 2018 | 43 | 1.940 |
Why?
|
| Central Nervous System Depressants | 8 | 2019 | 14 | 1.850 |
Why?
|
| Middle Aged | 98 | 2021 | 7910 | 1.840 |
Why?
|
| alpha-Synuclein | 9 | 2022 | 103 | 1.820 |
Why?
|
| Melatonin | 6 | 2016 | 91 | 1.810 |
Why?
|
| Cell Membrane Permeability | 10 | 2015 | 50 | 1.750 |
Why?
|
| Sleep Wake Disorders | 6 | 2020 | 109 | 1.720 |
Why?
|
| Fatty Liver | 9 | 2019 | 26 | 1.590 |
Why?
|
| Circadian Clocks | 7 | 2022 | 20 | 1.570 |
Why?
|
| Fatty Acids, Volatile | 13 | 2023 | 26 | 1.550 |
Why?
|
| Photoperiod | 6 | 2021 | 28 | 1.500 |
Why?
|
| Actins | 10 | 2007 | 35 | 1.490 |
Why?
|
| Disease Models, Animal | 23 | 2023 | 523 | 1.480 |
Why?
|
| Colitis | 15 | 2023 | 25 | 1.470 |
Why?
|
| Dietary Fiber | 11 | 2023 | 25 | 1.450 |
Why?
|
| Reactive Oxygen Species | 18 | 2011 | 104 | 1.410 |
Why?
|
| Metabolic Syndrome | 2 | 2023 | 55 | 1.410 |
Why?
|
| Crohn Disease | 17 | 2021 | 37 | 1.390 |
Why?
|
| NF-kappa B | 10 | 2022 | 102 | 1.380 |
Why?
|
| Prebiotics | 7 | 2023 | 18 | 1.350 |
Why?
|
| Mast Cells | 8 | 2018 | 18 | 1.350 |
Why?
|
| Nitric Oxide Synthase Type II | 12 | 2015 | 62 | 1.340 |
Why?
|
| Stress, Psychological | 6 | 2022 | 206 | 1.330 |
Why?
|
| MicroRNAs | 5 | 2015 | 37 | 1.310 |
Why?
|
| Isoenzymes | 10 | 2005 | 50 | 1.290 |
Why?
|
| Multiple System Atrophy | 2 | 2022 | 26 | 1.230 |
Why?
|
| Time Factors | 27 | 2020 | 1262 | 1.220 |
Why?
|
| Sleep | 8 | 2021 | 268 | 1.220 |
Why?
|
| Colon, Sigmoid | 5 | 2020 | 11 | 1.200 |
Why?
|
| Nitric Oxide | 10 | 2009 | 72 | 1.180 |
Why?
|
| CLOCK Proteins | 6 | 2018 | 11 | 1.150 |
Why?
|
| Mindfulness | 2 | 2022 | 46 | 1.130 |
Why?
|
| Work Schedule Tolerance | 2 | 2020 | 23 | 1.120 |
Why?
|
| Eating | 5 | 2021 | 46 | 1.100 |
Why?
|
| Biomarkers | 16 | 2021 | 476 | 1.090 |
Why?
|
| Colonic Neoplasms | 8 | 2014 | 56 | 1.090 |
Why?
|
| Metabolome | 4 | 2015 | 9 | 1.080 |
Why?
|
| Cytochrome P-450 CYP2E1 | 4 | 2014 | 7 | 1.060 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2018 | 30 | 1.060 |
Why?
|
| Obesity | 7 | 2023 | 289 | 1.040 |
Why?
|
| HIV Infections | 12 | 2020 | 431 | 1.020 |
Why?
|
| Chronobiology Disorders | 3 | 2017 | 13 | 1.000 |
Why?
|
| Hydrogen Peroxide | 16 | 2007 | 40 | 0.990 |
Why?
|
| Period Circadian Proteins | 5 | 2021 | 11 | 0.970 |
Why?
|
| Volatile Organic Compounds | 3 | 2015 | 8 | 0.950 |
Why?
|
| Nitric Oxide Synthase | 9 | 2004 | 42 | 0.950 |
Why?
|
| Diarrhea | 9 | 2011 | 31 | 0.930 |
Why?
|
| Intestinal Diseases | 3 | 2017 | 7 | 0.920 |
Why?
|
| Esophagus | 15 | 2010 | 53 | 0.910 |
Why?
|
| Aged | 51 | 2021 | 7447 | 0.890 |
Why?
|
| Membrane Glycoproteins | 4 | 2021 | 50 | 0.890 |
Why?
|
| Antioxidants | 9 | 2006 | 56 | 0.890 |
Why?
|
| Sinusitis | 5 | 2018 | 151 | 0.890 |
Why?
|
| Signal Transduction | 12 | 2022 | 398 | 0.880 |
Why?
|
| Intestine, Small | 8 | 2019 | 30 | 0.870 |
Why?
|
| Chronic Disease | 21 | 2020 | 375 | 0.870 |
Why?
|
| Carrier Proteins | 3 | 2021 | 88 | 0.860 |
Why?
|
| Starch | 4 | 2019 | 9 | 0.830 |
Why?
|
| Oligosaccharides | 6 | 2022 | 10 | 0.820 |
Why?
|
| Food Hypersensitivity | 7 | 2021 | 40 | 0.820 |
Why?
|
| Neurosecretory Systems | 2 | 2022 | 5 | 0.820 |
Why?
|
| Rats | 26 | 2020 | 626 | 0.810 |
Why?
|
| Depression | 5 | 2018 | 368 | 0.800 |
Why?
|
| Colorectal Neoplasms | 4 | 2018 | 106 | 0.790 |
Why?
|
| Mercaptopurine | 1 | 2023 | 3 | 0.790 |
Why?
|
| Rhinitis | 4 | 2018 | 136 | 0.780 |
Why?
|
| Young Adult | 17 | 2018 | 1651 | 0.780 |
Why?
|
| Life Style | 2 | 2022 | 159 | 0.750 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 9 | 0.750 |
Why?
|
| Biopsy | 16 | 2018 | 186 | 0.730 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 147 | 0.730 |
Why?
|
| Carcinogenesis | 4 | 2019 | 20 | 0.720 |
Why?
|
| Case-Control Studies | 13 | 2021 | 481 | 0.720 |
Why?
|
| Circadian Rhythm Signaling Peptides and Proteins | 3 | 2019 | 8 | 0.720 |
Why?
|
| Gene Expression Regulation | 8 | 2019 | 232 | 0.720 |
Why?
|
| Diet | 10 | 2023 | 178 | 0.720 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2018 | 25 | 0.710 |
Why?
|
| Probiotics | 5 | 2018 | 15 | 0.710 |
Why?
|
| Metagenome | 8 | 2023 | 15 | 0.700 |
Why?
|
| Neutrophils | 12 | 2002 | 91 | 0.700 |
Why?
|
| Surveys and Questionnaires | 11 | 2021 | 1020 | 0.690 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2021 | 4 | 0.690 |
Why?
|
| I-kappa B Proteins | 5 | 2007 | 10 | 0.690 |
Why?
|
| Dopamine Agents | 2 | 2021 | 11 | 0.690 |
Why?
|
| Binge Drinking | 3 | 2019 | 8 | 0.690 |
Why?
|
| Microspheres | 3 | 2017 | 24 | 0.680 |
Why?
|
| Animal Husbandry | 1 | 2020 | 6 | 0.670 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2021 | 35 | 0.670 |
Why?
|
| Barrett Esophagus | 5 | 2010 | 16 | 0.670 |
Why?
|
| Stem Cells | 2 | 2017 | 34 | 0.670 |
Why?
|
| Irritable Bowel Syndrome | 3 | 2015 | 9 | 0.670 |
Why?
|
| Veterans | 1 | 2022 | 87 | 0.660 |
Why?
|
| Brain | 9 | 2023 | 1203 | 0.660 |
Why?
|
| Bacterial Translocation | 4 | 2015 | 18 | 0.660 |
Why?
|
| Weight Gain | 1 | 2020 | 61 | 0.650 |
Why?
|
| Fermentation | 8 | 2021 | 13 | 0.640 |
Why?
|
| Tight Junctions | 9 | 2022 | 18 | 0.640 |
Why?
|
| Macrophages | 2 | 2018 | 89 | 0.640 |
Why?
|
| Saliva | 3 | 2022 | 47 | 0.640 |
Why?
|
| Immunity, Mucosal | 5 | 2019 | 11 | 0.640 |
Why?
|
| Fatty Liver, Alcoholic | 4 | 2019 | 6 | 0.630 |
Why?
|
| Dermatitis, Atopic | 4 | 2021 | 10 | 0.630 |
Why?
|
| Rotenone | 2 | 2018 | 6 | 0.630 |
Why?
|
| Transcription Factors | 2 | 2011 | 149 | 0.620 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 1 | 2019 | 2 | 0.620 |
Why?
|
| Hepatitis, Alcoholic | 2 | 2013 | 2 | 0.610 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2022 | 219 | 0.600 |
Why?
|
| Severity of Illness Index | 9 | 2021 | 801 | 0.600 |
Why?
|
| Risk Factors | 13 | 2022 | 1970 | 0.600 |
Why?
|
| Chromatography, Gas | 5 | 2015 | 10 | 0.590 |
Why?
|
| Type C Phospholipases | 3 | 2004 | 8 | 0.590 |
Why?
|
| Nitrates | 6 | 2009 | 9 | 0.580 |
Why?
|
| Mutation | 3 | 2018 | 328 | 0.580 |
Why?
|
| Light | 2 | 2016 | 55 | 0.570 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 19 | 0.570 |
Why?
|
| Radiation Injuries | 2 | 2013 | 27 | 0.570 |
Why?
|
| RNA, Ribosomal, 16S | 9 | 2023 | 39 | 0.560 |
Why?
|
| Gastric Emptying | 8 | 1997 | 12 | 0.560 |
Why?
|
| Specimen Handling | 2 | 2019 | 39 | 0.560 |
Why?
|
| Neoplasms | 1 | 2020 | 216 | 0.560 |
Why?
|
| Muscle, Smooth | 8 | 1997 | 12 | 0.550 |
Why?
|
| Endotoxins | 5 | 2013 | 9 | 0.550 |
Why?
|
| Rats, Sprague-Dawley | 16 | 2011 | 315 | 0.550 |
Why?
|
| Organoids | 1 | 2017 | 7 | 0.550 |
Why?
|
| Complementary Therapies | 1 | 2017 | 7 | 0.540 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 28 | 0.540 |
Why?
|
| Feeding Behavior | 4 | 2019 | 78 | 0.540 |
Why?
|
| Transfection | 11 | 2004 | 117 | 0.530 |
Why?
|
| Butyrates | 6 | 2022 | 12 | 0.530 |
Why?
|
| Defecation | 1 | 2017 | 5 | 0.530 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 88 | 0.530 |
Why?
|
| Mice, Knockout | 9 | 2022 | 282 | 0.530 |
Why?
|
| Digestive System | 6 | 2010 | 14 | 0.520 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2017 | 4 | 0.520 |
Why?
|
| Nasal Obstruction | 1 | 2017 | 4 | 0.520 |
Why?
|
| Disease Progression | 9 | 2023 | 528 | 0.520 |
Why?
|
| Gastrointestinal Agents | 4 | 2013 | 9 | 0.510 |
Why?
|
| Hospitalization | 2 | 2016 | 286 | 0.510 |
Why?
|
| Solid Phase Microextraction | 2 | 2013 | 3 | 0.500 |
Why?
|
| Digestive System Diseases | 1 | 2016 | 5 | 0.500 |
Why?
|
| Avena | 3 | 2009 | 3 | 0.500 |
Why?
|
| Carbohydrates | 2 | 2021 | 5 | 0.500 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2016 | 15 | 0.490 |
Why?
|
| Cognitive Dysfunction | 2 | 2021 | 737 | 0.490 |
Why?
|
| Gastrointestinal Motility | 9 | 2020 | 13 | 0.480 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2016 | 46 | 0.470 |
Why?
|
| Gastroesophageal Reflux | 4 | 2004 | 27 | 0.470 |
Why?
|
| Diabetes Mellitus, Type 1 | 6 | 2018 | 15 | 0.470 |
Why?
|
| Colonic Diseases | 2 | 2009 | 7 | 0.460 |
Why?
|
| Esophageal Neoplasms | 3 | 2010 | 50 | 0.460 |
Why?
|
| Sexuality | 1 | 2015 | 14 | 0.450 |
Why?
|
| Carbohydrate Metabolism | 1 | 2015 | 4 | 0.450 |
Why?
|
| Urinalysis | 1 | 2015 | 7 | 0.450 |
Why?
|
| Cell Line, Tumor | 7 | 2018 | 244 | 0.450 |
Why?
|
| Body Image | 1 | 2015 | 27 | 0.450 |
Why?
|
| Infant, Premature | 1 | 2016 | 186 | 0.440 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2015 | 46 | 0.430 |
Why?
|
| Gastrointestinal Hemorrhage | 6 | 2012 | 22 | 0.430 |
Why?
|
| Enzyme Activation | 6 | 2004 | 109 | 0.430 |
Why?
|
| Models, Biological | 4 | 2010 | 303 | 0.430 |
Why?
|
| Tubulin | 9 | 2004 | 15 | 0.430 |
Why?
|
| Blotting, Western | 9 | 2007 | 131 | 0.430 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2016 | 172 | 0.430 |
Why?
|
| Sucrose | 8 | 2018 | 14 | 0.420 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2016 | 153 | 0.420 |
Why?
|
| Polymerase Chain Reaction | 4 | 2017 | 112 | 0.420 |
Why?
|
| Calcium | 5 | 2002 | 354 | 0.420 |
Why?
|
| Dextran Sulfate | 4 | 2023 | 6 | 0.420 |
Why?
|
| Mental Competency | 1 | 2013 | 9 | 0.420 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 3728 | 0.420 |
Why?
|
| Gastrointestinal Transit | 7 | 2012 | 12 | 0.410 |
Why?
|
| Luminescent Measurements | 14 | 2003 | 19 | 0.410 |
Why?
|
| Membrane Proteins | 5 | 2014 | 149 | 0.410 |
Why?
|
| Artifacts | 1 | 2013 | 29 | 0.410 |
Why?
|
| ErbB Receptors | 4 | 2009 | 54 | 0.410 |
Why?
|
| Immune System | 4 | 2021 | 11 | 0.410 |
Why?
|
| Patient Participation | 1 | 2013 | 43 | 0.400 |
Why?
|
| Tyrosine | 5 | 2011 | 22 | 0.400 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 69 | 0.400 |
Why?
|
| Colectomy | 3 | 2010 | 20 | 0.390 |
Why?
|
| Alcohol-Related Disorders | 1 | 2013 | 2 | 0.390 |
Why?
|
| Research Personnel | 1 | 2013 | 17 | 0.390 |
Why?
|
| Alzheimer Disease | 2 | 2021 | 1320 | 0.390 |
Why?
|
| Muscle Contraction | 7 | 2007 | 67 | 0.390 |
Why?
|
| Up-Regulation | 7 | 2018 | 144 | 0.390 |
Why?
|
| Career Choice | 1 | 2013 | 23 | 0.390 |
Why?
|
| Eosinophilia | 3 | 2003 | 36 | 0.390 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 165 | 0.390 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 260 | 0.380 |
Why?
|
| Lymphogranuloma Venereum | 1 | 2012 | 1 | 0.380 |
Why?
|
| Proctocolitis | 1 | 2012 | 1 | 0.380 |
Why?
|
| Biomedical Research | 1 | 2013 | 51 | 0.380 |
Why?
|
| Neurons | 2 | 2011 | 273 | 0.380 |
Why?
|
| Acute-Phase Proteins | 3 | 2021 | 9 | 0.380 |
Why?
|
| Chlamydia trachomatis | 1 | 2012 | 5 | 0.380 |
Why?
|
| Colonic Diseases, Functional | 2 | 2003 | 3 | 0.380 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 61 | 0.380 |
Why?
|
| Asthma | 5 | 2018 | 152 | 0.370 |
Why?
|
| Wound Healing | 2 | 2010 | 108 | 0.360 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 25 | 0.360 |
Why?
|
| Wine | 1 | 2011 | 6 | 0.360 |
Why?
|
| Proctocolectomy, Restorative | 2 | 2012 | 4 | 0.360 |
Why?
|
| Psychotherapy | 1 | 2011 | 38 | 0.350 |
Why?
|
| Esophagitis | 3 | 2003 | 6 | 0.350 |
Why?
|
| Physicians | 1 | 2013 | 105 | 0.350 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2006 | 67 | 0.350 |
Why?
|
| Chronotherapy | 2 | 2023 | 5 | 0.350 |
Why?
|
| Stress, Physiological | 5 | 2015 | 13 | 0.350 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 6 | 2016 | 87 | 0.350 |
Why?
|
| Treatment Outcome | 12 | 2022 | 2941 | 0.340 |
Why?
|
| Food | 5 | 2020 | 30 | 0.340 |
Why?
|
| Constipation | 6 | 2017 | 16 | 0.340 |
Why?
|
| Phosphodiesterase Inhibitors | 2 | 2007 | 14 | 0.330 |
Why?
|
| Osteoarthritis | 3 | 2021 | 283 | 0.330 |
Why?
|
| Body Mass Index | 3 | 2021 | 378 | 0.330 |
Why?
|
| Oxidation-Reduction | 9 | 2005 | 62 | 0.330 |
Why?
|
| Prospective Studies | 8 | 2023 | 1493 | 0.330 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2010 | 1 | 0.320 |
Why?
|
| Cytokines | 6 | 2017 | 202 | 0.320 |
Why?
|
| Lipopolysaccharides | 5 | 2022 | 85 | 0.320 |
Why?
|
| Drug Delivery Systems | 2 | 2007 | 26 | 0.320 |
Why?
|
| Mesalamine | 3 | 2008 | 3 | 0.310 |
Why?
|
| Mucous Membrane | 4 | 2019 | 24 | 0.310 |
Why?
|
| Levodopa | 2 | 2020 | 34 | 0.310 |
Why?
|
| Stomach | 5 | 2010 | 14 | 0.310 |
Why?
|
| Mesoderm | 1 | 2009 | 18 | 0.310 |
Why?
|
| Liver Cirrhosis, Alcoholic | 2 | 2000 | 4 | 0.310 |
Why?
|
| Antiparkinson Agents | 2 | 2020 | 41 | 0.310 |
Why?
|
| Fatty Acids | 4 | 2019 | 33 | 0.310 |
Why?
|
| Disease Susceptibility | 6 | 2018 | 56 | 0.310 |
Why?
|
| Ascorbic Acid | 2 | 2018 | 31 | 0.310 |
Why?
|
| Colonoscopy | 6 | 2018 | 72 | 0.310 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 760 | 0.300 |
Why?
|
| Cadherins | 2 | 2020 | 30 | 0.300 |
Why?
|
| Phosphorylation | 6 | 2005 | 131 | 0.300 |
Why?
|
| Laparoscopy | 5 | 2010 | 184 | 0.300 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 31 | 0.300 |
Why?
|
| Esophagectomy | 2 | 2010 | 23 | 0.300 |
Why?
|
| Cats | 11 | 1998 | 28 | 0.300 |
Why?
|
| Respiratory Burst | 3 | 2002 | 27 | 0.300 |
Why?
|
| Biomarkers, Tumor | 2 | 2009 | 200 | 0.300 |
Why?
|
| Sleep Deprivation | 1 | 2009 | 35 | 0.300 |
Why?
|
| Phytotherapy | 2 | 2006 | 11 | 0.290 |
Why?
|
| Enzyme Inhibitors | 6 | 2022 | 112 | 0.290 |
Why?
|
| Prevalence | 7 | 2018 | 375 | 0.290 |
Why?
|
| Adolescent | 13 | 2022 | 1881 | 0.290 |
Why?
|
| Dietary Supplements | 2 | 2021 | 53 | 0.290 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 2 | 2007 | 4 | 0.290 |
Why?
|
| Homeostasis | 4 | 2022 | 65 | 0.290 |
Why?
|
| Parkinsonian Disorders | 2 | 2021 | 164 | 0.290 |
Why?
|
| Peroxidase | 8 | 2009 | 15 | 0.290 |
Why?
|
| Esophageal Motility Disorders | 4 | 1993 | 4 | 0.280 |
Why?
|
| Health Status Disparities | 2 | 2021 | 63 | 0.280 |
Why?
|
| Glucose | 3 | 2020 | 43 | 0.280 |
Why?
|
| Healthy Volunteers | 3 | 2021 | 29 | 0.280 |
Why?
|
| Retrospective Studies | 15 | 2018 | 2994 | 0.270 |
Why?
|
| Hypnosis | 1 | 2007 | 1 | 0.270 |
Why?
|
| Diet, High-Fat | 3 | 2022 | 12 | 0.270 |
Why?
|
| Apoptosis | 5 | 2013 | 196 | 0.270 |
Why?
|
| Double-Blind Method | 5 | 2018 | 373 | 0.270 |
Why?
|
| Hypersensitivity | 1 | 2008 | 38 | 0.270 |
Why?
|
| Jejunal Diseases | 2 | 2003 | 3 | 0.270 |
Why?
|
| Pouchitis | 1 | 2007 | 2 | 0.260 |
Why?
|
| Colonic Pouches | 1 | 2007 | 2 | 0.260 |
Why?
|
| Cholecystectomy | 2 | 2021 | 10 | 0.260 |
Why?
|
| Random Allocation | 2 | 2020 | 103 | 0.260 |
Why?
|
| Cell Communication | 1 | 2007 | 21 | 0.260 |
Why?
|
| Metalloproteases | 1 | 2007 | 5 | 0.260 |
Why?
|
| Cytosol | 6 | 2004 | 40 | 0.260 |
Why?
|
| Luminol | 7 | 1997 | 7 | 0.260 |
Why?
|
| Analgesics | 2 | 2018 | 78 | 0.260 |
Why?
|
| Graft vs Host Disease | 1 | 2007 | 53 | 0.260 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 111 | 0.250 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2007 | 71 | 0.250 |
Why?
|
| Plant Preparations | 1 | 2006 | 7 | 0.250 |
Why?
|
| Cytoskeletal Proteins | 2 | 2004 | 13 | 0.250 |
Why?
|
| Lactulose | 6 | 2011 | 7 | 0.250 |
Why?
|
| Bacterial Infections | 2 | 2013 | 47 | 0.250 |
Why?
|
| Azathioprine | 2 | 2023 | 6 | 0.250 |
Why?
|
| Intestinal Obstruction | 2 | 2003 | 11 | 0.250 |
Why?
|
| Milk, Human | 2 | 2019 | 157 | 0.250 |
Why?
|
| Xylans | 2 | 2016 | 2 | 0.240 |
Why?
|
| Anxiety | 2 | 2018 | 143 | 0.240 |
Why?
|
| Enterocolitis | 1 | 2006 | 4 | 0.240 |
Why?
|
| Pilot Projects | 3 | 2023 | 370 | 0.240 |
Why?
|
| Duodenal Obstruction | 1 | 2006 | 1 | 0.240 |
Why?
|
| Mastocytosis, Systemic | 1 | 2006 | 6 | 0.240 |
Why?
|
| Esophagogastric Junction | 7 | 1996 | 13 | 0.240 |
Why?
|
| Vasculitis | 2 | 2002 | 26 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2017 | 315 | 0.240 |
Why?
|
| Fluorescent Antibody Technique | 5 | 2004 | 53 | 0.240 |
Why?
|
| HIV-1 | 2 | 2018 | 203 | 0.240 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2020 | 165 | 0.240 |
Why?
|
| Thiazoles | 2 | 2006 | 15 | 0.240 |
Why?
|
| Mannitol | 5 | 2011 | 11 | 0.240 |
Why?
|
| Microscopy, Confocal | 5 | 2004 | 80 | 0.240 |
Why?
|
| Toll-Like Receptors | 3 | 2014 | 17 | 0.230 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 392 | 0.230 |
Why?
|
| Gene Expression Profiling | 5 | 2018 | 110 | 0.230 |
Why?
|
| Endoscopy, Digestive System | 2 | 2003 | 7 | 0.230 |
Why?
|
| Microglia | 3 | 2022 | 108 | 0.230 |
Why?
|
| Cross-Over Studies | 2 | 2023 | 64 | 0.230 |
Why?
|
| Biodiversity | 3 | 2020 | 31 | 0.220 |
Why?
|
| Adaptation, Physiological | 2 | 2019 | 42 | 0.220 |
Why?
|
| Inflammation Mediators | 2 | 2016 | 58 | 0.220 |
Why?
|
| Zonula Occludens-1 Protein | 3 | 2017 | 10 | 0.220 |
Why?
|
| Stomach Ulcer | 2 | 1997 | 4 | 0.220 |
Why?
|
| Quinolones | 2 | 2002 | 11 | 0.220 |
Why?
|
| Alanine | 2 | 2002 | 12 | 0.220 |
Why?
|
| Peristalsis | 8 | 1996 | 11 | 0.220 |
Why?
|
| Infant | 4 | 2021 | 483 | 0.210 |
Why?
|
| Leptin | 2 | 2022 | 18 | 0.210 |
Why?
|
| Rectum | 5 | 2002 | 50 | 0.210 |
Why?
|
| Serotonin | 2 | 2023 | 22 | 0.210 |
Why?
|
| Colonic Polyps | 3 | 2019 | 29 | 0.210 |
Why?
|
| Milk | 2 | 2021 | 11 | 0.210 |
Why?
|
| Body Weight | 6 | 2019 | 129 | 0.210 |
Why?
|
| Esophagitis, Peptic | 3 | 2002 | 3 | 0.210 |
Why?
|
| Free Radical Scavengers | 3 | 2017 | 7 | 0.210 |
Why?
|
| Enterocytes | 1 | 2003 | 1 | 0.210 |
Why?
|
| Adipose Tissue | 2 | 2018 | 73 | 0.210 |
Why?
|
| Administration, Oral | 3 | 2016 | 97 | 0.210 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2014 | 94 | 0.200 |
Why?
|
| Gastric Bypass | 1 | 2004 | 68 | 0.200 |
Why?
|
| Reoperation | 2 | 2021 | 743 | 0.200 |
Why?
|
| Spinal Cord Injuries | 4 | 1998 | 37 | 0.200 |
Why?
|
| Indium | 5 | 1986 | 8 | 0.200 |
Why?
|
| Mice, Transgenic | 5 | 2019 | 173 | 0.200 |
Why?
|
| Radioisotopes | 5 | 1986 | 13 | 0.200 |
Why?
|
| Choristoma | 1 | 2003 | 4 | 0.200 |
Why?
|
| Central Nervous System | 1 | 2023 | 47 | 0.200 |
Why?
|
| Sigmoidoscopy | 4 | 2016 | 5 | 0.200 |
Why?
|
| Thioguanine | 1 | 2023 | 3 | 0.200 |
Why?
|
| Antibodies, Viral | 2 | 2021 | 48 | 0.200 |
Why?
|
| STAT3 Transcription Factor | 1 | 2023 | 11 | 0.200 |
Why?
|
| Kinetics | 3 | 2015 | 176 | 0.200 |
Why?
|
| Leukocyte L1 Antigen Complex | 2 | 2014 | 6 | 0.200 |
Why?
|
| Diagnosis, Differential | 5 | 2012 | 311 | 0.190 |
Why?
|
| Hygromycin B | 1 | 2002 | 2 | 0.190 |
Why?
|
| Oligonucleotides, Antisense | 4 | 2004 | 9 | 0.190 |
Why?
|
| Gastroenteritis | 2 | 1997 | 4 | 0.190 |
Why?
|
| Cinnamates | 1 | 2002 | 8 | 0.190 |
Why?
|
| Capillaries | 1 | 2002 | 10 | 0.190 |
Why?
|
| DNA Damage | 2 | 2019 | 25 | 0.190 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 4 | 2021 | 16 | 0.190 |
Why?
|
| Aspirin | 4 | 2016 | 50 | 0.190 |
Why?
|
| Cigarette Smoking | 1 | 2022 | 4 | 0.190 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 92 | 0.190 |
Why?
|
| Protein Kinase C beta | 4 | 2003 | 8 | 0.190 |
Why?
|
| beta-Glucans | 1 | 2022 | 25 | 0.190 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 439 | 0.190 |
Why?
|
| Heart Transplantation | 2 | 1993 | 30 | 0.190 |
Why?
|
| Longitudinal Studies | 3 | 2016 | 1046 | 0.190 |
Why?
|
| Osteogenesis | 1 | 2022 | 99 | 0.180 |
Why?
|
| Choline | 1 | 2022 | 4 | 0.180 |
Why?
|
| Hydrogen-Ion Concentration | 7 | 2016 | 125 | 0.180 |
Why?
|
| Neutrophil Activation | 3 | 1999 | 6 | 0.180 |
Why?
|
| Shift Work Schedule | 1 | 2022 | 7 | 0.180 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 14 | 0.180 |
Why?
|
| Mouth | 1 | 2022 | 12 | 0.180 |
Why?
|
| Manometry | 9 | 1997 | 15 | 0.180 |
Why?
|
| DNA-Binding Proteins | 3 | 2019 | 228 | 0.180 |
Why?
|
| Immunologic Factors | 2 | 2019 | 19 | 0.180 |
Why?
|
| Vitamin E | 2 | 2001 | 37 | 0.180 |
Why?
|
| Mice, Inbred NOD | 2 | 2018 | 24 | 0.180 |
Why?
|
| Edible Grain | 2 | 2013 | 4 | 0.180 |
Why?
|
| Interferon Type I | 2 | 2018 | 9 | 0.180 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 42 | 0.180 |
Why?
|
| Cells, Cultured | 4 | 2017 | 468 | 0.180 |
Why?
|
| Acute Disease | 6 | 2009 | 163 | 0.180 |
Why?
|
| Granulocytes | 3 | 1986 | 15 | 0.180 |
Why?
|
| Pancreas | 2 | 2018 | 30 | 0.180 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2019 | 22 | 0.170 |
Why?
|
| Proton Pump Inhibitors | 2 | 2016 | 11 | 0.170 |
Why?
|
| Proctitis | 1 | 2001 | 3 | 0.170 |
Why?
|
| Cohort Studies | 6 | 2023 | 1417 | 0.170 |
Why?
|
| Dietary Sucrose | 2 | 2014 | 5 | 0.170 |
Why?
|
| Clostridium | 1 | 2020 | 1 | 0.170 |
Why?
|
| Immunity, Innate | 1 | 2021 | 55 | 0.170 |
Why?
|
| Transaminases | 1 | 2020 | 6 | 0.170 |
Why?
|
| Protective Agents | 2 | 2018 | 8 | 0.170 |
Why?
|
| Snail Family Transcription Factors | 2 | 2011 | 3 | 0.170 |
Why?
|
| Memory, Short-Term | 1 | 2021 | 79 | 0.170 |
Why?
|
| Duodenal Ulcer | 2 | 1990 | 2 | 0.160 |
Why?
|
| Bone Density | 1 | 2021 | 146 | 0.160 |
Why?
|
| Wnt Signaling Pathway | 2 | 2018 | 29 | 0.160 |
Why?
|
| Drug Therapy, Combination | 4 | 2018 | 162 | 0.160 |
Why?
|
| Gastric Mucosa | 5 | 2010 | 9 | 0.160 |
Why?
|
| Macaca mulatta | 1 | 2020 | 56 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 111 | 0.160 |
Why?
|
| Insulin | 1 | 2020 | 77 | 0.160 |
Why?
|
| Risk Assessment | 3 | 2010 | 548 | 0.160 |
Why?
|
| Esophageal Achalasia | 2 | 2004 | 17 | 0.160 |
Why?
|
| Alcoholic Intoxication | 3 | 2016 | 8 | 0.160 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2020 | 2 | 0.160 |
Why?
|
| Subcellular Fractions | 3 | 2004 | 16 | 0.160 |
Why?
|
| Blood Glucose | 1 | 2020 | 99 | 0.160 |
Why?
|
| Inflammasomes | 1 | 2020 | 9 | 0.160 |
Why?
|
| Cell Proliferation | 2 | 2018 | 163 | 0.160 |
Why?
|
| Collagen Diseases | 2 | 1993 | 2 | 0.160 |
Why?
|
| Occludin | 2 | 2017 | 8 | 0.160 |
Why?
|
| Radionuclide Imaging | 9 | 1997 | 41 | 0.160 |
Why?
|
| Zea mays | 2 | 2016 | 2 | 0.160 |
Why?
|
| Growth Substances | 1 | 1999 | 27 | 0.160 |
Why?
|
| Killer Cells, Natural | 2 | 2023 | 40 | 0.160 |
Why?
|
| Fructose | 2 | 2019 | 4 | 0.160 |
Why?
|
| Reference Values | 6 | 2007 | 169 | 0.160 |
Why?
|
| Histone Deacetylases | 1 | 2019 | 11 | 0.160 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 3 | 2015 | 10 | 0.160 |
Why?
|
| Cognition | 3 | 2021 | 948 | 0.160 |
Why?
|
| Immunosuppressive Agents | 3 | 2007 | 113 | 0.150 |
Why?
|
| DNA, Bacterial | 2 | 2017 | 37 | 0.150 |
Why?
|
| Aging | 2 | 2018 | 1102 | 0.150 |
Why?
|
| Osteolysis | 1 | 2020 | 113 | 0.150 |
Why?
|
| Trisaccharides | 1 | 2019 | 1 | 0.150 |
Why?
|
| Astronauts | 1 | 2019 | 2 | 0.150 |
Why?
|
| Jejunum | 2 | 2017 | 10 | 0.150 |
Why?
|
| Space Flight | 1 | 2019 | 4 | 0.150 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 9 | 0.150 |
Why?
|
| Prostheses and Implants | 1 | 2020 | 132 | 0.150 |
Why?
|
| Interleukin-8 | 1 | 1999 | 14 | 0.150 |
Why?
|
| Tyrosine Decarboxylase | 1 | 2019 | 1 | 0.150 |
Why?
|
| Prognosis | 3 | 2013 | 730 | 0.150 |
Why?
|
| Lymphocyte Activation | 3 | 2014 | 76 | 0.150 |
Why?
|
| Firmicutes | 1 | 2019 | 5 | 0.150 |
Why?
|
| RNA, Small Interfering | 2 | 2011 | 76 | 0.150 |
Why?
|
| CD3 Complex | 1 | 2018 | 2 | 0.150 |
Why?
|
| Phospholipase C gamma | 3 | 2004 | 6 | 0.150 |
Why?
|
| Vaccination | 2 | 2019 | 26 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2019 | 40 | 0.150 |
Why?
|
| Child | 6 | 2021 | 1157 | 0.150 |
Why?
|
| Liver Diseases | 3 | 2002 | 33 | 0.150 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 35 | 0.150 |
Why?
|
| Lectins | 1 | 2018 | 5 | 0.150 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 5 | 0.150 |
Why?
|
| RAW 264.7 Cells | 1 | 2018 | 3 | 0.140 |
Why?
|
| Jet Lag Syndrome | 1 | 2018 | 11 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 11 | 0.140 |
Why?
|
| Bifidobacterium | 1 | 2018 | 2 | 0.140 |
Why?
|
| Synbiotics | 1 | 2018 | 2 | 0.140 |
Why?
|
| Immunoblotting | 4 | 2005 | 54 | 0.140 |
Why?
|
| Mice, SCID | 1 | 2018 | 39 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2018 | 49 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2018 | 51 | 0.140 |
Why?
|
| Glutathione | 1 | 1998 | 23 | 0.140 |
Why?
|
| DNA | 2 | 2017 | 95 | 0.140 |
Why?
|
| Perception | 1 | 2018 | 64 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 15 | 0.140 |
Why?
|
| Prosthesis-Related Infections | 1 | 2020 | 177 | 0.140 |
Why?
|
| Behavior, Addictive | 1 | 2018 | 8 | 0.140 |
Why?
|
| Bisacodyl | 1 | 2018 | 1 | 0.140 |
Why?
|
| Isotonic Solutions | 1 | 2018 | 8 | 0.140 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2018 | 6 | 0.140 |
Why?
|
| Gastric Acid | 4 | 2002 | 9 | 0.140 |
Why?
|
| Cathartics | 1 | 2018 | 7 | 0.140 |
Why?
|
| Rhinitis, Allergic | 1 | 2018 | 14 | 0.140 |
Why?
|
| Transcription Factor HES-1 | 1 | 2017 | 2 | 0.140 |
Why?
|
| Keratin-20 | 1 | 2017 | 2 | 0.140 |
Why?
|
| Receptor, Notch1 | 1 | 2017 | 4 | 0.140 |
Why?
|
| B-Lymphocytes | 2 | 2019 | 50 | 0.140 |
Why?
|
| Chromogranin A | 1 | 2017 | 8 | 0.140 |
Why?
|
| Animal Feed | 1 | 2017 | 1 | 0.140 |
Why?
|
| Hypercholesterolemia | 1 | 2018 | 20 | 0.140 |
Why?
|
| Iodide Peroxidase | 1 | 2019 | 112 | 0.140 |
Why?
|
| Protein Kinases | 1 | 2017 | 11 | 0.140 |
Why?
|
| Cell Lineage | 1 | 2017 | 25 | 0.140 |
Why?
|
| Nose | 1 | 2018 | 32 | 0.140 |
Why?
|
| Tetradecanoylphorbol Acetate | 4 | 2001 | 30 | 0.140 |
Why?
|
| Methamphetamine | 1 | 2018 | 22 | 0.140 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2017 | 11 | 0.140 |
Why?
|
| Bone and Bones | 1 | 2018 | 107 | 0.140 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 36 | 0.140 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2017 | 6 | 0.130 |
Why?
|
| Mitomycin | 3 | 1996 | 10 | 0.130 |
Why?
|
| Kidney | 1 | 2018 | 142 | 0.130 |
Why?
|
| Kupffer Cells | 1 | 2017 | 2 | 0.130 |
Why?
|
| Fissure in Ano | 1 | 2017 | 1 | 0.130 |
Why?
|
| Diazepam | 1 | 2017 | 5 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 57 | 0.130 |
Why?
|
| Hepatocytes | 1 | 2017 | 10 | 0.130 |
Why?
|
| Cytomegalovirus Infections | 1 | 2017 | 27 | 0.130 |
Why?
|
| Candida | 1 | 2017 | 16 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2018 | 107 | 0.130 |
Why?
|
| Uridine | 1 | 2017 | 1 | 0.130 |
Why?
|
| Fish Oils | 1 | 2017 | 4 | 0.130 |
Why?
|
| Viral Load | 4 | 2020 | 70 | 0.130 |
Why?
|
| Carbonated Beverages | 1 | 1997 | 2 | 0.130 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2009 | 10 | 0.130 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 1412 | 0.130 |
Why?
|
| Oxalic Acid | 1 | 2016 | 1 | 0.130 |
Why?
|
| Enteral Nutrition | 2 | 1998 | 60 | 0.130 |
Why?
|
| Biological Transport | 3 | 2003 | 38 | 0.130 |
Why?
|
| Antibodies | 2 | 2023 | 43 | 0.130 |
Why?
|
| Arthralgia | 1 | 2018 | 100 | 0.130 |
Why?
|
| Logistic Models | 3 | 2016 | 351 | 0.130 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 4 | 1997 | 12 | 0.130 |
Why?
|
| Substance Withdrawal Syndrome | 3 | 1994 | 34 | 0.130 |
Why?
|
| Catalase | 2 | 1995 | 5 | 0.130 |
Why?
|
| Actin Cytoskeleton | 2 | 2009 | 6 | 0.130 |
Why?
|
| Military Personnel | 2 | 2015 | 37 | 0.120 |
Why?
|
| Hydroxyurea | 1 | 1996 | 29 | 0.120 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 1996 | 7 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 31 | 0.120 |
Why?
|
| Rats, Inbred F344 | 5 | 2018 | 33 | 0.120 |
Why?
|
| Methane | 1 | 2016 | 2 | 0.120 |
Why?
|
| Diverticulum | 1 | 2016 | 3 | 0.120 |
Why?
|
| Colitis, Microscopic | 1 | 2016 | 1 | 0.120 |
Why?
|
| Enteric Nervous System | 2 | 2017 | 5 | 0.120 |
Why?
|
| Photic Stimulation | 1 | 2016 | 22 | 0.120 |
Why?
|
| Mice, Mutant Strains | 1 | 2016 | 19 | 0.120 |
Why?
|
| Blood Alcohol Content | 1 | 2016 | 1 | 0.120 |
Why?
|
| Birth Weight | 1 | 2016 | 38 | 0.120 |
Why?
|
| Nitrogen | 1 | 1995 | 4 | 0.120 |
Why?
|
| Blood Cells | 1 | 1995 | 3 | 0.120 |
Why?
|
| NF-KappaB Inhibitor alpha | 3 | 2007 | 7 | 0.120 |
Why?
|
| Phylogeny | 1 | 2016 | 44 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 88 | 0.120 |
Why?
|
| Erythromycin | 2 | 1993 | 4 | 0.120 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2015 | 4 | 0.120 |
Why?
|
| Neural Inhibition | 1 | 1995 | 8 | 0.120 |
Why?
|
| Nasal Mucosa | 1 | 2016 | 13 | 0.120 |
Why?
|
| Hydrocortisone | 2 | 2014 | 29 | 0.120 |
Why?
|
| Gestational Age | 1 | 2016 | 73 | 0.120 |
Why?
|
| Employment | 1 | 2016 | 38 | 0.120 |
Why?
|
| Resins, Synthetic | 1 | 1995 | 1 | 0.120 |
Why?
|
| Dietary Proteins | 2 | 2006 | 26 | 0.120 |
Why?
|
| Indium Radioisotopes | 1 | 1995 | 5 | 0.120 |
Why?
|
| Income | 1 | 2016 | 63 | 0.120 |
Why?
|
| Protein Folding | 1 | 2015 | 16 | 0.120 |
Why?
|
| Nasal Polyps | 1 | 2016 | 51 | 0.120 |
Why?
|
| Cell Movement | 3 | 2013 | 77 | 0.110 |
Why?
|
| Liver Function Tests | 3 | 2004 | 21 | 0.110 |
Why?
|
| Alkanes | 1 | 2015 | 2 | 0.110 |
Why?
|
| Terpenes | 1 | 2015 | 3 | 0.110 |
Why?
|
| Sesquiterpenes | 1 | 2015 | 4 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 48 | 0.110 |
Why?
|
| Sulfides | 1 | 2015 | 10 | 0.110 |
Why?
|
| Fatty Alcohols | 1 | 2015 | 5 | 0.110 |
Why?
|
| Cell Line | 2 | 2009 | 250 | 0.110 |
Why?
|
| Gene Expression | 3 | 2007 | 178 | 0.110 |
Why?
|
| Disulfides | 1 | 2015 | 10 | 0.110 |
Why?
|
| Caudovirales | 1 | 2015 | 2 | 0.110 |
Why?
|
| Microviridae | 1 | 2015 | 2 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2012 | 362 | 0.110 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 13 | 0.110 |
Why?
|
| Pattern Recognition, Automated | 1 | 2015 | 7 | 0.110 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 256 | 0.110 |
Why?
|
| Educational Status | 1 | 2016 | 209 | 0.110 |
Why?
|
| Hepatitis B Vaccines | 1 | 2014 | 3 | 0.110 |
Why?
|
| Protein Kinase C-theta | 2 | 2005 | 2 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2016 | 171 | 0.110 |
Why?
|
| Hepatitis B | 1 | 2014 | 12 | 0.110 |
Why?
|
| Gastrointestinal Absorption | 1 | 2014 | 1 | 0.110 |
Why?
|
| Free Radicals | 4 | 2003 | 7 | 0.110 |
Why?
|
| Joints | 1 | 2015 | 67 | 0.110 |
Why?
|
| Polyradiculoneuropathy | 1 | 1994 | 2 | 0.110 |
Why?
|
| Protein Isoforms | 2 | 2005 | 36 | 0.110 |
Why?
|
| HT29 Cells | 3 | 2018 | 8 | 0.110 |
Why?
|
| Breath Tests | 5 | 2016 | 10 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 132 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 2 | 2007 | 69 | 0.110 |
Why?
|
| T-Lymphocytes | 2 | 2006 | 94 | 0.110 |
Why?
|
| Myocardial Ischemia | 1 | 2015 | 44 | 0.110 |
Why?
|
| Vagus Nerve | 2 | 2013 | 14 | 0.110 |
Why?
|
| Eosinophils | 2 | 2003 | 36 | 0.110 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 4 | 0.110 |
Why?
|
| Sex Characteristics | 1 | 2015 | 85 | 0.110 |
Why?
|
| Flow Cytometry | 4 | 2014 | 102 | 0.110 |
Why?
|
| Interleukins | 1 | 2014 | 21 | 0.110 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2007 | 7 | 0.110 |
Why?
|
| Infant, Newborn | 1 | 2016 | 537 | 0.110 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 18 | 0.100 |
Why?
|
| Hippocampus | 1 | 2015 | 198 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2007 | 336 | 0.100 |
Why?
|
| Plasmids | 2 | 2004 | 42 | 0.100 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 2 | 2003 | 4 | 0.100 |
Why?
|
| Serine | 2 | 2003 | 9 | 0.100 |
Why?
|
| Cell Nucleus | 2 | 2004 | 70 | 0.100 |
Why?
|
| Smoking | 1 | 2015 | 161 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 97 | 0.100 |
Why?
|
| Intubation, Gastrointestinal | 2 | 1993 | 11 | 0.100 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 171 | 0.100 |
Why?
|
| Biota | 1 | 2013 | 4 | 0.100 |
Why?
|
| Anti-Retroviral Agents | 1 | 2013 | 15 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 1993 | 34 | 0.100 |
Why?
|
| beta Catenin | 1 | 2014 | 57 | 0.100 |
Why?
|
| Drug Resistance | 2 | 2017 | 45 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2013 | 284 | 0.100 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 442 | 0.100 |
Why?
|
| Physical Education and Training | 1 | 2013 | 4 | 0.100 |
Why?
|
| Attention | 1 | 2014 | 101 | 0.100 |
Why?
|
| B-Lymphocytes, Regulatory | 1 | 2013 | 2 | 0.100 |
Why?
|
| Child, Preschool | 3 | 2021 | 567 | 0.100 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 1993 | 11 | 0.100 |
Why?
|
| Bacteriological Techniques | 2 | 2012 | 15 | 0.100 |
Why?
|
| Amifostine | 1 | 1992 | 3 | 0.100 |
Why?
|
| Salicylates | 1 | 1992 | 6 | 0.100 |
Why?
|
| Protein Kinase C-delta | 2 | 2003 | 10 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 44 | 0.100 |
Why?
|
| Superoxides | 3 | 2000 | 23 | 0.100 |
Why?
|
| Capsule Endoscopy | 1 | 2012 | 5 | 0.100 |
Why?
|
| Biofilms | 2 | 2016 | 13 | 0.100 |
Why?
|
| Unsafe Sex | 1 | 2012 | 2 | 0.090 |
Why?
|
| Deglutition Disorders | 3 | 2003 | 30 | 0.090 |
Why?
|
| Cartilage, Articular | 1 | 2015 | 267 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2016 | 219 | 0.090 |
Why?
|
| Social Support | 1 | 2013 | 174 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 57 | 0.090 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2012 | 3 | 0.090 |
Why?
|
| Algorithms | 3 | 2015 | 304 | 0.090 |
Why?
|
| Homosexuality, Male | 1 | 2012 | 24 | 0.090 |
Why?
|
| Coinfection | 1 | 2012 | 20 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2012 | 25 | 0.090 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2023 | 6 | 0.090 |
Why?
|
| Peptic Ulcer | 1 | 1992 | 4 | 0.090 |
Why?
|
| Osteoarthritis, Knee | 1 | 2015 | 299 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 592 | 0.090 |
Why?
|
| Receptors, Cholinergic | 1 | 1992 | 24 | 0.090 |
Why?
|
| Postoperative Complications | 3 | 2012 | 811 | 0.090 |
Why?
|
| Escherichia coli Infections | 1 | 2011 | 25 | 0.090 |
Why?
|
| Cholelithiasis | 1 | 1991 | 6 | 0.090 |
Why?
|
| Phosphoproteins | 2 | 2011 | 23 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 32 | 0.090 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2020 | 33 | 0.090 |
Why?
|
| Portal Vein | 1 | 2012 | 45 | 0.090 |
Why?
|
| Escherichia coli | 1 | 2011 | 43 | 0.090 |
Why?
|
| Lysine | 1 | 2011 | 14 | 0.090 |
Why?
|
| Particulate Matter | 1 | 2011 | 16 | 0.090 |
Why?
|
| p21-Activated Kinases | 1 | 2011 | 6 | 0.090 |
Why?
|
| Knee Joint | 1 | 2015 | 572 | 0.090 |
Why?
|
| Tryptases | 2 | 2013 | 5 | 0.090 |
Why?
|
| Drug Interactions | 3 | 2006 | 35 | 0.090 |
Why?
|
| Catheterization | 3 | 2003 | 40 | 0.090 |
Why?
|
| In Vitro Techniques | 4 | 2015 | 153 | 0.090 |
Why?
|
| Gallbladder | 2 | 1987 | 3 | 0.080 |
Why?
|
| Prostaglandins | 1 | 1990 | 3 | 0.080 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 2 | 2007 | 5 | 0.080 |
Why?
|
| Nitrites | 2 | 2009 | 3 | 0.080 |
Why?
|
| Cell Death | 3 | 2011 | 34 | 0.080 |
Why?
|
| Diabetic Neuropathies | 5 | 1987 | 11 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 104 | 0.080 |
Why?
|
| Oral Hygiene | 1 | 2010 | 4 | 0.080 |
Why?
|
| Ileum | 3 | 2017 | 16 | 0.080 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 8 | 0.080 |
Why?
|
| Receptors, Muscarinic | 1 | 1990 | 2 | 0.080 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2010 | 6 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 124 | 0.080 |
Why?
|
| Anastomotic Leak | 1 | 2010 | 6 | 0.080 |
Why?
|
| Dopamine Antagonists | 1 | 1990 | 5 | 0.080 |
Why?
|
| Serotonin Antagonists | 1 | 1990 | 8 | 0.080 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 10 | 0.080 |
Why?
|
| Lectins, C-Type | 2 | 2022 | 50 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 37 | 0.080 |
Why?
|
| Norepinephrine | 1 | 1990 | 28 | 0.080 |
Why?
|
| Deficiency Diseases | 1 | 2010 | 1 | 0.080 |
Why?
|
| Oxygen | 1 | 1990 | 56 | 0.080 |
Why?
|
| MPTP Poisoning | 1 | 1990 | 13 | 0.080 |
Why?
|
| Gastrostomy | 1 | 1989 | 9 | 0.080 |
Why?
|
| Cecum | 2 | 2019 | 11 | 0.080 |
Why?
|
| Celiac Disease | 2 | 2016 | 7 | 0.080 |
Why?
|
| Sodium Pertechnetate Tc 99m | 1 | 1989 | 1 | 0.080 |
Why?
|
| Models, Statistical | 2 | 2007 | 113 | 0.080 |
Why?
|
| Cell Count | 2 | 2007 | 72 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2013 | 215 | 0.080 |
Why?
|
| Rectal Diseases | 1 | 2009 | 1 | 0.080 |
Why?
|
| Abnormalities, Multiple | 2 | 2006 | 13 | 0.080 |
Why?
|
| Protein Carbonylation | 1 | 2009 | 1 | 0.080 |
Why?
|
| Clinical Trials as Topic | 3 | 2006 | 190 | 0.070 |
Why?
|
| Organ Size | 1 | 2009 | 87 | 0.070 |
Why?
|
| Biological Availability | 1 | 2008 | 16 | 0.070 |
Why?
|
| Malabsorption Syndromes | 1 | 1988 | 1 | 0.070 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 1988 | 1 | 0.070 |
Why?
|
| Amylases | 1 | 1988 | 5 | 0.070 |
Why?
|
| Spectrophotometry | 2 | 2007 | 5 | 0.070 |
Why?
|
| Dietary Carbohydrates | 1 | 1988 | 11 | 0.070 |
Why?
|
| Fundoplication | 2 | 2010 | 21 | 0.070 |
Why?
|
| Intestinal Pseudo-Obstruction | 2 | 1990 | 3 | 0.070 |
Why?
|
| United States | 2 | 2019 | 1765 | 0.070 |
Why?
|
| Macrophage-1 Antigen | 2 | 1999 | 7 | 0.070 |
Why?
|
| Metabolomics | 2 | 2021 | 6 | 0.070 |
Why?
|
| Gram-Negative Bacteria | 1 | 2008 | 26 | 0.070 |
Why?
|
| Metagenomics | 2 | 2020 | 6 | 0.070 |
Why?
|
| South Africa | 2 | 2018 | 7 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2012 | 577 | 0.070 |
Why?
|
| Tyrosine 3-Monooxygenase | 2 | 2021 | 51 | 0.070 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2008 | 5 | 0.070 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2008 | 6 | 0.070 |
Why?
|
| Phenotype | 2 | 2021 | 260 | 0.070 |
Why?
|
| Leukocytes | 2 | 1985 | 30 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2007 | 38 | 0.070 |
Why?
|
| Carbachol | 3 | 1996 | 4 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2007 | 15 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2007 | 89 | 0.070 |
Why?
|
| DNA, Viral | 2 | 2017 | 39 | 0.070 |
Why?
|
| Lactobacillus | 2 | 2019 | 15 | 0.070 |
Why?
|
| Quinidine | 1 | 2007 | 2 | 0.070 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2007 | 3 | 0.070 |
Why?
|
| Substantia Nigra | 2 | 2022 | 101 | 0.070 |
Why?
|
| Esophageal Diseases | 1 | 1987 | 4 | 0.070 |
Why?
|
| Age Factors | 2 | 2021 | 635 | 0.070 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2007 | 27 | 0.070 |
Why?
|
| ADAM17 Protein | 1 | 2007 | 2 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 12 | 0.060 |
Why?
|
| Behavior | 1 | 2007 | 21 | 0.060 |
Why?
|
| Intercellular Junctions | 1 | 2007 | 8 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2007 | 16 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 22 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2007 | 28 | 0.060 |
Why?
|
| Cattle | 1 | 2007 | 111 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2007 | 210 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 198 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2007 | 27 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 26 | 0.060 |
Why?
|
| Coculture Techniques | 2 | 2018 | 30 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2007 | 95 | 0.060 |
Why?
|
| Sleep Stages | 1 | 2006 | 19 | 0.060 |
Why?
|
| ADAM Proteins | 1 | 2007 | 41 | 0.060 |
Why?
|
| Herbal Medicine | 1 | 2006 | 2 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 101 | 0.060 |
Why?
|
| Lipid Metabolism | 2 | 2019 | 34 | 0.060 |
Why?
|
| Lactose Intolerance | 1 | 1986 | 1 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2006 | 26 | 0.060 |
Why?
|
| Aspartate Aminotransferases | 1 | 2006 | 13 | 0.060 |
Why?
|
| Serum Albumin | 1 | 2006 | 21 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2006 | 15 | 0.060 |
Why?
|
| Ranitidine | 1 | 2006 | 3 | 0.060 |
Why?
|
| Cetirizine | 1 | 2006 | 3 | 0.060 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2006 | 3 | 0.060 |
Why?
|
| Duodenum | 1 | 2006 | 5 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 138 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2007 | 104 | 0.060 |
Why?
|
| Pancreatitis | 2 | 2002 | 20 | 0.060 |
Why?
|
| Growth Disorders | 1 | 2006 | 3 | 0.060 |
Why?
|
| Serine Endopeptidases | 1 | 2006 | 14 | 0.060 |
Why?
|
| Organometallic Compounds | 1 | 1986 | 17 | 0.060 |
Why?
|
| Culture Techniques | 2 | 1996 | 19 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2006 | 44 | 0.060 |
Why?
|
| Syndrome | 1 | 2006 | 68 | 0.060 |
Why?
|
| Health | 2 | 2021 | 8 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2007 | 173 | 0.060 |
Why?
|
| Amino Acids | 2 | 2001 | 18 | 0.060 |
Why?
|
| Sex Factors | 2 | 2021 | 384 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2018 | 87 | 0.060 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2019 | 8 | 0.060 |
Why?
|
| Remission Induction | 2 | 2006 | 89 | 0.060 |
Why?
|
| Claudin-4 | 1 | 2005 | 1 | 0.060 |
Why?
|
| Claudin-1 | 1 | 2005 | 2 | 0.060 |
Why?
|
| Host-Pathogen Interactions | 2 | 2016 | 10 | 0.060 |
Why?
|
| Ribonucleases | 1 | 1985 | 6 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 33 | 0.060 |
Why?
|
| Proteoglycans | 2 | 2015 | 120 | 0.060 |
Why?
|
| Pituitary Gland | 1 | 2005 | 14 | 0.060 |
Why?
|
| Tertiary Care Centers | 2 | 2016 | 66 | 0.060 |
Why?
|
| Hepatic Encephalopathy | 1 | 1984 | 3 | 0.060 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2004 | 7 | 0.060 |
Why?
|
| Hepatitis | 1 | 2004 | 5 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2004 | 19 | 0.060 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2004 | 12 | 0.050 |
Why?
|
| Organ Specificity | 2 | 2015 | 34 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2004 | 63 | 0.050 |
Why?
|
| Leukocyte Count | 2 | 1996 | 58 | 0.050 |
Why?
|
| Genes, Dominant | 1 | 2004 | 10 | 0.050 |
Why?
|
| Enzyme Stability | 1 | 2004 | 4 | 0.050 |
Why?
|
| Protein Subunits | 1 | 2004 | 17 | 0.050 |
Why?
|
| Leiomyoma | 1 | 2004 | 5 | 0.050 |
Why?
|
| Incidence | 2 | 2018 | 624 | 0.050 |
Why?
|
| Histamine H1 Antagonists | 1 | 2003 | 2 | 0.050 |
Why?
|
| Budesonide | 1 | 2003 | 3 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2003 | 4 | 0.050 |
Why?
|
| Histamine H2 Antagonists | 1 | 2003 | 6 | 0.050 |
Why?
|
| Esophageal Perforation | 1 | 2003 | 8 | 0.050 |
Why?
|
| Proton Pumps | 1 | 2003 | 12 | 0.050 |
Why?
|
| Ileostomy | 1 | 1983 | 1 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2023 | 11 | 0.050 |
Why?
|
| Indomethacin | 1 | 1983 | 2 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2004 | 28 | 0.050 |
Why?
|
| Metronidazole | 1 | 1983 | 5 | 0.050 |
Why?
|
| Phosphoinositide Phospholipase C | 1 | 2003 | 1 | 0.050 |
Why?
|
| Cytoprotection | 1 | 2003 | 9 | 0.050 |
Why?
|
| Prednisone | 1 | 2003 | 64 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2004 | 32 | 0.050 |
Why?
|
| Proteins | 2 | 2005 | 52 | 0.050 |
Why?
|
| Intracellular Membranes | 1 | 2003 | 20 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2003 | 32 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2006 | 251 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2013 | 29 | 0.050 |
Why?
|
| Gastroscopy | 2 | 1997 | 9 | 0.050 |
Why?
|
| Fluorometry | 1 | 2003 | 5 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2003 | 10 | 0.050 |
Why?
|
| Cell Survival | 2 | 2001 | 99 | 0.050 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2023 | 2 | 0.050 |
Why?
|
| Anastomosis, Surgical | 1 | 2003 | 27 | 0.050 |
Why?
|
| Laparotomy | 1 | 2003 | 17 | 0.050 |
Why?
|
| Autonomic Nervous System Diseases | 3 | 1987 | 24 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2003 | 56 | 0.050 |
Why?
|
| ARNTL Transcription Factors | 1 | 2022 | 6 | 0.050 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 3 | 1987 | 8 | 0.050 |
Why?
|
| Recurrence | 1 | 2003 | 268 | 0.050 |
Why?
|
| Tetracycline | 1 | 2002 | 2 | 0.050 |
Why?
|
| Aminoglycosides | 1 | 2002 | 10 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2002 | 38 | 0.050 |
Why?
|
| Syk Kinase | 1 | 2022 | 11 | 0.050 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 2022 | 4 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2022 | 13 | 0.050 |
Why?
|
| Environment | 2 | 2015 | 36 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2022 | 12 | 0.050 |
Why?
|
| Diglycerides | 1 | 2002 | 1 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 164 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2002 | 31 | 0.050 |
Why?
|
| Methylamines | 1 | 2022 | 2 | 0.050 |
Why?
|
| Lyases | 1 | 2022 | 7 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2022 | 9 | 0.050 |
Why?
|
| Sweden | 1 | 2021 | 6 | 0.050 |
Why?
|
| Metalloporphyrins | 1 | 2001 | 2 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 95 | 0.050 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2021 | 17 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 1993 | 49 | 0.040 |
Why?
|
| Enzyme Activators | 1 | 2001 | 1 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2013 | 26 | 0.040 |
Why?
|
| RGS Proteins | 1 | 2021 | 2 | 0.040 |
Why?
|
| CD8 Antigens | 1 | 2021 | 11 | 0.040 |
Why?
|
| Acupuncture Therapy | 1 | 2001 | 2 | 0.040 |
Why?
|
| Glycomics | 1 | 2021 | 1 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2021 | 16 | 0.040 |
Why?
|
| Atropine | 2 | 1992 | 3 | 0.040 |
Why?
|
| Haptoglobins | 1 | 2021 | 2 | 0.040 |
Why?
|
| Lung | 1 | 2022 | 138 | 0.040 |
Why?
|
| Disease | 1 | 2021 | 6 | 0.040 |
Why?
|
| Central Nervous System Agents | 1 | 2001 | 7 | 0.040 |
Why?
|
| Suprachiasmatic Nucleus | 1 | 2021 | 10 | 0.040 |
Why?
|
| Luciferases | 1 | 2021 | 25 | 0.040 |
Why?
|
| Hypochlorous Acid | 1 | 2001 | 1 | 0.040 |
Why?
|
| Calcimycin | 1 | 2001 | 4 | 0.040 |
Why?
|
| Protein Kinase C-alpha | 1 | 2001 | 8 | 0.040 |
Why?
|
| Maleimides | 1 | 2001 | 6 | 0.040 |
Why?
|
| Publications | 1 | 2021 | 13 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2001 | 12 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2021 | 17 | 0.040 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2021 | 3 | 0.040 |
Why?
|
| Calcium-Transporting ATPases | 1 | 2001 | 17 | 0.040 |
Why?
|
| Complement Activation | 1 | 2021 | 7 | 0.040 |
Why?
|
| Receptors, Fc | 1 | 2021 | 6 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2021 | 21 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2002 | 83 | 0.040 |
Why?
|
| Pasteurization | 1 | 2021 | 1 | 0.040 |
Why?
|
| Urbanization | 1 | 2021 | 1 | 0.040 |
Why?
|
| Dust | 1 | 2021 | 2 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 72 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 15 | 0.040 |
Why?
|
| Phagocytosis | 1 | 2021 | 25 | 0.040 |
Why?
|
| Indoles | 1 | 2001 | 32 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 17 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 125 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2004 | 292 | 0.040 |
Why?
|
| Albumins | 1 | 2021 | 18 | 0.040 |
Why?
|
| Dopamine | 1 | 2021 | 77 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 164 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2001 | 37 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2001 | 34 | 0.040 |
Why?
|
| Lipid Peroxidation | 2 | 2005 | 6 | 0.040 |
Why?
|
| Deamination | 1 | 2020 | 1 | 0.040 |
Why?
|
| Pregnancy | 1 | 2021 | 324 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2001 | 87 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2021 | 73 | 0.040 |
Why?
|
| Anilides | 1 | 2020 | 5 | 0.040 |
Why?
|
| Registries | 1 | 2021 | 173 | 0.040 |
Why?
|
| Illinois | 2 | 2016 | 221 | 0.040 |
Why?
|
| Digestion | 2 | 2013 | 2 | 0.040 |
Why?
|
| Neurotoxins | 1 | 2020 | 13 | 0.040 |
Why?
|
| Administration, Topical | 2 | 2017 | 14 | 0.040 |
Why?
|
| Fasting | 2 | 1993 | 19 | 0.040 |
Why?
|
| Pyridines | 1 | 2020 | 27 | 0.040 |
Why?
|
| Fluorescence | 1 | 2000 | 8 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 2020 | 47 | 0.040 |
Why?
|
| Glycosylation | 1 | 2020 | 16 | 0.040 |
Why?
|
| Mental Health | 1 | 2021 | 94 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2020 | 14 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 72 | 0.040 |
Why?
|
| Colchicine | 1 | 2000 | 10 | 0.040 |
Why?
|
| Proteobacteria | 1 | 2019 | 1 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2000 | 49 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2019 | 18 | 0.040 |
Why?
|
| Cell Degranulation | 2 | 2013 | 6 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 42 | 0.040 |
Why?
|
| Diet Therapy | 1 | 2019 | 10 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 60 | 0.040 |
Why?
|
| Transcriptome | 1 | 2020 | 53 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 50 | 0.040 |
Why?
|
| Freezing | 1 | 2019 | 11 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 206 | 0.040 |
Why?
|
| Pain | 2 | 2017 | 332 | 0.040 |
Why?
|
| Galactose | 1 | 2019 | 2 | 0.040 |
Why?
|
| United States National Aeronautics and Space Administration | 1 | 2019 | 1 | 0.040 |
Why?
|
| Telomere Homeostasis | 1 | 2019 | 1 | 0.040 |
Why?
|
| Calcium Channels | 2 | 1997 | 106 | 0.040 |
Why?
|
| Genomic Instability | 1 | 2019 | 8 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2019 | 14 | 0.040 |
Why?
|
| Dialysis Solutions | 1 | 1999 | 3 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2019 | 12 | 0.040 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2019 | 17 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2019 | 23 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2019 | 6 | 0.040 |
Why?
|
| Motor Activity | 1 | 2021 | 267 | 0.040 |
Why?
|
| Solanum tuberosum | 1 | 2019 | 2 | 0.040 |
Why?
|
| Triglycerides | 1 | 2019 | 54 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 67 | 0.040 |
Why?
|
| Particle Size | 2 | 2011 | 38 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2021 | 414 | 0.040 |
Why?
|
| Electric Stimulation | 1 | 1998 | 46 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2018 | 12 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 17 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 24 | 0.040 |
Why?
|
| Mitochondria | 2 | 2011 | 55 | 0.040 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 3 | 0.040 |
Why?
|
| Anion Exchange Resins | 1 | 1998 | 2 | 0.040 |
Why?
|
| Colestipol | 1 | 1998 | 2 | 0.040 |
Why?
|
| Acetic Acid | 2 | 2001 | 2 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 1998 | 7 | 0.040 |
Why?
|
| Bone Development | 1 | 2018 | 29 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2018 | 11 | 0.040 |
Why?
|
| NAV1.8 Voltage-Gated Sodium Channel | 1 | 2018 | 6 | 0.040 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2018 | 19 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 860 | 0.030 |
Why?
|
| Self Administration | 1 | 2018 | 16 | 0.030 |
Why?
|
| Electrolytes | 1 | 2018 | 11 | 0.030 |
Why?
|
| Rats, Transgenic | 1 | 2018 | 17 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2019 | 129 | 0.030 |
Why?
|
| Cytoplasm | 1 | 1997 | 33 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 2017 | 4 | 0.030 |
Why?
|
| Myxovirus Resistance Proteins | 1 | 2017 | 1 | 0.030 |
Why?
|
| Receptors, Formyl Peptide | 1 | 1997 | 1 | 0.030 |
Why?
|
| Receptors, Peptide | 1 | 1997 | 2 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 153 | 0.030 |
Why?
|
| Ubiquitins | 1 | 2017 | 8 | 0.030 |
Why?
|
| Oligopeptides | 1 | 1997 | 21 | 0.030 |
Why?
|
| Pyloric Antrum | 1 | 1997 | 2 | 0.030 |
Why?
|
| Receptors, Immunologic | 1 | 1997 | 15 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 1994 | 228 | 0.030 |
Why?
|
| Hyperalgesia | 1 | 2018 | 46 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 295 | 0.030 |
Why?
|
| Hip Prosthesis | 1 | 2021 | 437 | 0.030 |
Why?
|
| Docosahexaenoic Acids | 1 | 2017 | 7 | 0.030 |
Why?
|
| Cat Diseases | 1 | 1997 | 4 | 0.030 |
Why?
|
| Dipyridamole | 1 | 1997 | 2 | 0.030 |
Why?
|
| beta Carotene | 1 | 1997 | 12 | 0.030 |
Why?
|
| Genotype | 1 | 2018 | 248 | 0.030 |
Why?
|
| Electrodes, Implanted | 1 | 1997 | 20 | 0.030 |
Why?
|
| Catheters, Indwelling | 1 | 1997 | 20 | 0.030 |
Why?
|
| Butyric Acid | 1 | 2016 | 1 | 0.030 |
Why?
|
| Food Handling | 1 | 2016 | 2 | 0.030 |
Why?
|
| Diverticulum, Colon | 1 | 1996 | 1 | 0.030 |
Why?
|
| Muscle Relaxation | 1 | 1996 | 3 | 0.030 |
Why?
|
| Propionates | 1 | 2016 | 11 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2017 | 74 | 0.030 |
Why?
|
| Outpatients | 1 | 2017 | 56 | 0.030 |
Why?
|
| Linear Models | 2 | 2013 | 193 | 0.030 |
Why?
|
| Leukotriene B4 | 1 | 1996 | 3 | 0.030 |
Why?
|
| Factor X Deficiency | 1 | 1996 | 1 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 1996 | 8 | 0.030 |
Why?
|
| Amyloidosis | 1 | 1996 | 11 | 0.030 |
Why?
|
| Hemophilia B | 1 | 1996 | 10 | 0.030 |
Why?
|
| Substance P | 2 | 2012 | 10 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2016 | 3 | 0.030 |
Why?
|
| Fungi | 1 | 2016 | 3 | 0.030 |
Why?
|
| Viruses | 1 | 2016 | 5 | 0.030 |
Why?
|
| Chloramines | 1 | 1995 | 1 | 0.030 |
Why?
|
| Cyclic GMP | 1 | 1995 | 3 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2017 | 128 | 0.030 |
Why?
|
| Hippurates | 1 | 2015 | 1 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 40 | 0.030 |
Why?
|
| Ion Transport | 1 | 1995 | 28 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2015 | 8 | 0.030 |
Why?
|
| Phenylacetates | 1 | 2015 | 5 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 162 | 0.030 |
Why?
|
| Azides | 1 | 1995 | 2 | 0.030 |
Why?
|
| Dialysis | 1 | 1995 | 3 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 42 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2016 | 72 | 0.030 |
Why?
|
| Oryza | 1 | 2015 | 1 | 0.030 |
Why?
|
| Triticum | 1 | 2015 | 1 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2015 | 7 | 0.030 |
Why?
|
| Rheumatic Diseases | 1 | 2016 | 52 | 0.030 |
Why?
|
| Anions | 1 | 1995 | 4 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 256 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2015 | 5 | 0.030 |
Why?
|
| Alprostadil | 2 | 1995 | 9 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2017 | 412 | 0.030 |
Why?
|
| Ethane | 1 | 1994 | 1 | 0.030 |
Why?
|
| Pentanes | 1 | 1994 | 1 | 0.030 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 5 | 0.030 |
Why?
|
| Galectins | 1 | 2014 | 4 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2014 | 8 | 0.030 |
Why?
|
| Hypertension | 1 | 2016 | 163 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 1994 | 28 | 0.030 |
Why?
|
| Herpesvirus 3, Human | 1 | 1994 | 4 | 0.030 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2021 | 686 | 0.030 |
Why?
|
| Research Design | 1 | 2016 | 157 | 0.030 |
Why?
|
| Temperance | 1 | 1994 | 1 | 0.030 |
Why?
|
| Genes, APC | 1 | 2014 | 1 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2014 | 1 | 0.030 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2014 | 5 | 0.030 |
Why?
|
| Binding Sites | 1 | 2014 | 68 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2014 | 82 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2014 | 23 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2013 | 10 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1993 | 6 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 122 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 30 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2005 | 15 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 1996 | 11 | 0.030 |
Why?
|
| Piroxicam | 1 | 2013 | 5 | 0.020 |
Why?
|
| Chromones | 1 | 2013 | 9 | 0.020 |
Why?
|
| Enterobacteriaceae | 1 | 2013 | 40 | 0.020 |
Why?
|
| Morpholines | 1 | 2013 | 14 | 0.020 |
Why?
|
| Singapore | 1 | 2013 | 4 | 0.020 |
Why?
|
| CD40 Ligand | 1 | 2013 | 7 | 0.020 |
Why?
|
| B7-H1 Antigen | 1 | 2013 | 7 | 0.020 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 18 | 0.020 |
Why?
|
| Adherens Junctions | 1 | 2013 | 3 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2013 | 18 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2013 | 25 | 0.020 |
Why?
|
| Cell Division | 1 | 1993 | 80 | 0.020 |
Why?
|
| Acetates | 1 | 1992 | 16 | 0.020 |
Why?
|
| HIV | 1 | 2013 | 39 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2013 | 76 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2012 | 28 | 0.020 |
Why?
|
| Neurites | 1 | 2012 | 5 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 2 | 2007 | 97 | 0.020 |
Why?
|
| Quinuclidinyl Benzilate | 1 | 1992 | 1 | 0.020 |
Why?
|
| Bethanechol | 1 | 1992 | 3 | 0.020 |
Why?
|
| Bethanechol Compounds | 1 | 1992 | 3 | 0.020 |
Why?
|
| Pirenzepine | 1 | 1992 | 5 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1992 | 21 | 0.020 |
Why?
|
| Anti-Ulcer Agents | 1 | 1992 | 1 | 0.020 |
Why?
|
| Chicago | 1 | 2014 | 813 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2013 | 163 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2013 | 163 | 0.020 |
Why?
|
| District of Columbia | 1 | 2011 | 2 | 0.020 |
Why?
|
| Inpatients | 1 | 2012 | 113 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2011 | 24 | 0.020 |
Why?
|
| Flame Ionization | 1 | 2011 | 1 | 0.020 |
Why?
|
| Sterilization | 1 | 2011 | 7 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2011 | 17 | 0.020 |
Why?
|
| Air Pollution | 1 | 2011 | 14 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 22 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2011 | 70 | 0.020 |
Why?
|
| Omeprazole | 1 | 1990 | 1 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1991 | 64 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 1991 | 286 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1992 | 135 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 1990 | 21 | 0.020 |
Why?
|
| Misoprostol | 1 | 1990 | 5 | 0.020 |
Why?
|
| Hydroxides | 1 | 1990 | 1 | 0.020 |
Why?
|
| Hydroxyl Radical | 1 | 1990 | 1 | 0.020 |
Why?
|
| Xanthine Oxidase | 1 | 1990 | 2 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2010 | 10 | 0.020 |
Why?
|
| Vagotomy, Truncal | 1 | 1990 | 1 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 1990 | 2 | 0.020 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1990 | 16 | 0.020 |
Why?
|
| Diaphragm | 1 | 1990 | 8 | 0.020 |
Why?
|
| Dogs | 1 | 1990 | 136 | 0.020 |
Why?
|
| Health Surveys | 1 | 2010 | 77 | 0.020 |
Why?
|
| Endometriosis | 1 | 1990 | 15 | 0.020 |
Why?
|
| Muscular Diseases | 1 | 1990 | 12 | 0.020 |
Why?
|
| Peptide Mapping | 1 | 2009 | 4 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 28 | 0.020 |
Why?
|
| Delayed-Action Preparations | 2 | 2005 | 28 | 0.020 |
Why?
|
| Acetaldehyde | 1 | 2008 | 1 | 0.020 |
Why?
|
| Glutamine | 1 | 2008 | 6 | 0.020 |
Why?
|
| Burns | 1 | 2008 | 15 | 0.020 |
Why?
|
| Zinc | 1 | 2008 | 39 | 0.020 |
Why?
|
| Chemotactic Factors | 1 | 1988 | 1 | 0.020 |
Why?
|
| Lysosomes | 1 | 1988 | 20 | 0.020 |
Why?
|
| Electric Stimulation Therapy | 2 | 1998 | 39 | 0.020 |
Why?
|
| Diabetic Retinopathy | 1 | 1987 | 5 | 0.020 |
Why?
|
| Nutrition Disorders | 1 | 1987 | 3 | 0.020 |
Why?
|
| Xenopus laevis | 1 | 2007 | 4 | 0.020 |
Why?
|
| Deglutition | 1 | 1987 | 10 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2007 | 95 | 0.020 |
Why?
|
| Occult Blood | 1 | 1987 | 3 | 0.020 |
Why?
|
| Erythrocyte Indices | 1 | 1987 | 4 | 0.020 |
Why?
|
| Stomach Diseases | 1 | 1987 | 2 | 0.020 |
Why?
|
| Paresis | 1 | 1987 | 16 | 0.020 |
Why?
|
| Placebos | 1 | 2006 | 63 | 0.020 |
Why?
|
| Tumor Necrosis Factors | 1 | 2006 | 1 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 10c | 1 | 2006 | 1 | 0.020 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2006 | 2 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2006 | 6 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2006 | 16 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2006 | 10 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2006 | 5 | 0.020 |
Why?
|
| Nausea | 1 | 1986 | 24 | 0.020 |
Why?
|
| Hydrogen | 1 | 1986 | 6 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2006 | 16 | 0.020 |
Why?
|
| Vomiting | 1 | 1986 | 18 | 0.020 |
Why?
|
| West Indies | 1 | 1986 | 1 | 0.020 |
Why?
|
| Enoxaparin | 1 | 2006 | 3 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2006 | 5 | 0.020 |
Why?
|
| India | 1 | 1986 | 16 | 0.020 |
Why?
|
| Tropolone | 1 | 1986 | 1 | 0.020 |
Why?
|
| Intestinal Perforation | 1 | 1986 | 2 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2006 | 20 | 0.020 |
Why?
|
| United Kingdom | 1 | 1986 | 40 | 0.020 |
Why?
|
| Aminosalicylic Acids | 1 | 1986 | 1 | 0.020 |
Why?
|
| Physical Fitness | 1 | 2006 | 47 | 0.020 |
Why?
|
| Intestinal Neoplasms | 1 | 1986 | 12 | 0.020 |
Why?
|
| Autoradiography | 1 | 1985 | 5 | 0.020 |
Why?
|
| Cholestasis | 1 | 1985 | 7 | 0.020 |
Why?
|
| Warfarin | 1 | 2006 | 25 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2006 | 40 | 0.020 |
Why?
|
| Excipients | 1 | 2005 | 1 | 0.010 |
Why?
|
| Chemistry, Physical | 1 | 2005 | 2 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 2005 | 4 | 0.010 |
Why?
|
| Stochastic Processes | 1 | 2005 | 13 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1987 | 204 | 0.010 |
Why?
|
| Polymers | 1 | 2005 | 36 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2005 | 48 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2005 | 5 | 0.010 |
Why?
|
| Cold Temperature | 1 | 2005 | 27 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 1987 | 121 | 0.010 |
Why?
|
| Liver Abscess | 1 | 1985 | 1 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2006 | 82 | 0.010 |
Why?
|
| Anemia, Hypochromic | 1 | 1985 | 1 | 0.010 |
Why?
|
| Eosinophil Granule Proteins | 1 | 1985 | 1 | 0.010 |
Why?
|
| Cromolyn Sodium | 1 | 1985 | 2 | 0.010 |
Why?
|
| Prednisolone | 1 | 1985 | 8 | 0.010 |
Why?
|
| Blood Proteins | 1 | 1985 | 17 | 0.010 |
Why?
|
| Nucleic Acids | 1 | 2005 | 1 | 0.010 |
Why?
|
| Nucleosides | 1 | 2005 | 2 | 0.010 |
Why?
|
| Dinitrophenols | 1 | 2005 | 2 | 0.010 |
Why?
|
| Aldehydes | 1 | 2005 | 2 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 2005 | 12 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2005 | 22 | 0.010 |
Why?
|
| Heart Rate | 1 | 2005 | 104 | 0.010 |
Why?
|
| Ammonia | 1 | 1984 | 3 | 0.010 |
Why?
|
| Testosterone | 1 | 2005 | 27 | 0.010 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 1984 | 1 | 0.010 |
Why?
|
| Behcet Syndrome | 1 | 1984 | 3 | 0.010 |
Why?
|
| Abdomen | 1 | 1984 | 7 | 0.010 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 1984 | 9 | 0.010 |
Why?
|
| Amoxicillin | 1 | 1984 | 1 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2005 | 166 | 0.010 |
Why?
|
| Electroencephalography | 1 | 1984 | 70 | 0.010 |
Why?
|
| Exercise | 1 | 2006 | 392 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1984 | 173 | 0.010 |
Why?
|
| Plasma Cells | 1 | 2001 | 5 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 2001 | 10 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2001 | 16 | 0.010 |
Why?
|
| Portal System | 1 | 2000 | 1 | 0.010 |
Why?
|
| Cyclooxygenase 1 | 1 | 2000 | 6 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2000 | 19 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2000 | 12 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2000 | 23 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2000 | 54 | 0.010 |
Why?
|
| Phenylhydrazines | 1 | 1999 | 1 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1999 | 5 | 0.010 |
Why?
|
| Enema | 1 | 1997 | 2 | 0.010 |
Why?
|
| Nimodipine | 1 | 1997 | 1 | 0.010 |
Why?
|
| Vitamin A | 1 | 1997 | 7 | 0.010 |
Why?
|
| Tretinoin | 1 | 1997 | 15 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 1996 | 2 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 1996 | 30 | 0.010 |
Why?
|
| Patient Compliance | 1 | 1997 | 146 | 0.010 |
Why?
|
| Calcinosis | 1 | 1996 | 43 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1996 | 237 | 0.010 |
Why?
|
| Secretory Rate | 1 | 1995 | 1 | 0.010 |
Why?
|
| Theophylline | 1 | 1995 | 2 | 0.010 |
Why?
|
| Bradykinin | 1 | 1995 | 2 | 0.010 |
Why?
|
| Second Messenger Systems | 1 | 1995 | 6 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1988 | 11 | 0.000 |
Why?
|
| Biological Assay | 1 | 1988 | 7 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1988 | 22 | 0.000 |
Why?
|
| Plasma Exchange | 1 | 1987 | 11 | 0.000 |
Why?
|
| Renal Dialysis | 1 | 1987 | 82 | 0.000 |
Why?
|
| Blood Sedimentation | 1 | 1986 | 49 | 0.000 |
Why?
|
| Radiography | 1 | 1985 | 521 | 0.000 |
Why?
|